Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response.

医学 胰腺癌 临床试验 生物标志物 肿瘤科 精密医学 叶黄素 内科学 化疗 癌症
作者
Toni T. Seppälä,Jacquelyn W. Zimmerman,Reecha Suri,Haley Zlomke,Gabriel D Ivey,Annamaria Szabolcs,Christopher R Shubert,John L Cameron,William R Burns,Kelly J. Lafaro,Jin He,Christopher L Wolfgang,Ying S Zou,Lei Zheng,David A. Tuveson,James R Eshlemann,David P Ryan,Alec C Kimmelman,Theodore S. Hong,David T. Ting,Elizabeth M. Jaffee,Richard A. Burkhart
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-21-4165
摘要

Patient-derived organoids (PDOs) are a promising technology to support precision medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may improve clinical next-generation sequencing (NGS) and enable rapid ex vivo chemotherapeutic screening (pharmacotyping).PDOs were derived from tissues obtained during surgical resection and endoscopic biopsies and studied with NGS and pharmacotyping. PDO-specific pharmacotype is assessed prospectively as a predictive biomarker of clinical therapeutic response by leveraging data from a randomized-controlled clinical trial.Clinical sequencing pipelines often fail to detect PDAC-associated somatic mutations in surgical specimens that demonstrate a good pathological response to previously administered chemotherapy. Sequencing the PDOs derived from these surgical specimens, after biomass expansion, improves the detection of somatic mutations and enables quantification of copy number variants. The detection of clinically relevant mutations and structural variants is improved following PDO biomass expansion. On clinical trial, PDOs were derived from biopsies of treatment naïve patients prior to treatment with FOLFIRINOX (FFX). Ex vivo PDO pharmacotyping with FFX components predicted clinical therapeutic response in these patients with borderline resectable or locally advanced PDAC treated in a neoadjuvant or induction paradigm. PDO pharmacotypes suggesting sensitivity to FFX components were associated with longitudinal declines of tumor marker, CA-19-9 and favorable RECIST imaging response.PDOs establishment from tissues obtained from patients previously receiving cytotoxic chemotherapies can be accomplished in a clinically-certified laboratory. Sequencing PDOs following biomass expansion improves clinical sequencing quality. High in-vitro sensitivity to standard-of-care chemotherapeutics predicts good clinical response to systemic chemotherapy in PDAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
康谨完成签到,获得积分10
刚刚
1秒前
bohe发布了新的文献求助10
1秒前
冬至完成签到 ,获得积分10
2秒前
2秒前
xirongyang完成签到,获得积分10
2秒前
充电宝的应助被玛卡采纳,获得10
2秒前
勿忘发布了新的文献求助10
2秒前
瀚子完成签到,获得积分10
3秒前
无花果的应助被芋泥啵啵采纳,获得10
3秒前
gouerde完成签到,获得积分10
3秒前
哎呀发布了新的文献求助10
3秒前
大模型的应助被HouMeng采纳,获得10
4秒前
4秒前
5秒前
5秒前
朋友发布了新的文献求助10
5秒前
6秒前
ZCTMWY发布了新的文献求助10
6秒前
星辰大海的应助被年年采纳,获得10
7秒前
nuoyefenfei发布了新的文献求助10
7秒前
7秒前
秋风的应助被徐世业采纳,获得20
8秒前
田様的应助被gouerde采纳,获得10
9秒前
369ninja发布了新的文献求助10
9秒前
thesky发布了新的文献求助10
10秒前
健忘兔子发布了新的文献求助10
10秒前
11秒前
传奇3的应助被Lu采纳,获得10
13秒前
jiawei1026完成签到,获得积分10
13秒前
初景发布了新的文献求助10
15秒前
无敌干扰素完成签到,获得积分10
15秒前
bkagyin的应助被嘎嘣脆采纳,获得10
16秒前
余香的应助被勤奋的翠绿采纳,获得10
17秒前
月见发布了新的文献求助10
17秒前
17秒前
霸气小松鼠关注了科研通微信公众号
17秒前
17秒前
123456789完成签到,获得积分10
18秒前
小马甲的应助被机智毛豆采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814